加纳肺炎球菌的病因概况:系统性审查
Reuben E Arhin1,2, Eric S Donkor1, Hans-Christian Slotved3
1Department of Medical Microbiology University of Ghana Medical School, Korle Bu, Ghana.
BioMed research international
|September 4, 2024
概括
这项研究分析了加纳的肺炎杆菌 (Streptococcus pneumoniae),揭示了显著的肺炎球菌携带者和疾病流行率. 抗菌素耐药性很高,非疫苗血清型在PCV-13引入后占主导地位,突出显示需要持续监测.
科学领域:
- 微生物学 微生物学
- 流行病学 流行病学
- 公共卫生 公共卫生
背景情况:
- 肺炎链球菌 (Streptococcus pneumoniae) 仍然是一个重要的全球病原体,导致大量的发病率和死亡率.
- 了解肺炎球菌的流行病学,携带和抗菌素耐药性对于有效的疾病控制策略至关重要.
研究的目的:
- 为了描述加纳肺炎链球菌 (Streptococcus pneumoniae) 的特征.
- 确定研究缺口,并提供有关肺炎球菌疾病方面的见解.
- 评估运输流行,疾病发病率和抗菌素耐药性模式.
主要方法:
- 通过使用谷歌学者,PubMed和ScienceDirect进行了系统的文献搜索.
- 数据提取集中在报告样本采集,种群特征,携带,疾病发病率,血清型和抗菌素敏感性的研究上.
- 从7954个初始结果中,共选出了24篇文章.
主要成果:
- 加纳的肺炎球菌携带者患病率在不同人群中从11.0%到51.4%不等.
- 对青素不敏感的分离物体在17%至63%之间,多药性耐药性高达100%.
- 在携带 (43.9%) 和侵入性肺炎球菌病 (IPD) 病例 (4.4%) 中,非PCV-13血清型占主导地位,这表明疫苗引入后的潜在挑战.
结论:
- 分子类型测定对于预测肺炎球菌的侵入性和了解囊切换对疾病负担的影响至关重要.
- 通过表型,基因型和分子方法对抗生素耐药性和血清型分布的持续监测对于加纳肺炎球菌疾病监测至关重要.
相关概念视频
01:30Pneumonia III: Complications and Assessment
189
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
189
01:30Pneumonia I: Introduction
214
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
214
01:29Pneumonia II: Pathophysiology
235
The pathophysiology of pneumonia involves the following steps:
235
01:28Pneumonia IV: Management
311
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
311